Shots:
- Hologic to acquire Diagenode for ~$159M. The transaction will expand and diversifies Hologic’s diagnostic business across test menu, customer segments and geography
- The acquisition will strengthen Hologic’s molecular diagnostics business by expanding international its capabilities and allow it to offer a broader more differentiated test menu
- Diagenode and Hologic previously collaborated to develop Hologic’s Panther Fusion assays for detecting streptococcus and Bordetella
Click here to read full press release/ article | Ref: Businesswire | Image: Hologic
The post Hologic to Acquire Diagenode for ~$159M first appeared on PharmaShots.
